In this insightful episode of the London Futurists podcast, Karl Pfleger—an investor and founder of the comprehensive database AgingBiotech.Info—shares his expertise on the evolving field of rejuvenation biotechnology. With a rich background in computer science and AI, Karl discusses the growth, challenges, and future of longevity science.

Key Points:

The longevity sector is experiencing unprecedented momentum but still awaits its first major therapeutic breakthrough. Increased public awareness and collaborative innovation could accelerate progress in addressing aging's root causes.

• The Mission of Rejuvenation Biotechnology: Pfleger advocates for rejuvenation therapies capable of restoring youthful health, aiming to help current generations and not just slow aging for the future.
• Rapid Expansion of the Longevity Sector: The field has grown significantly over the last decade, with a sharp increase in funding, companies, and clinical trials. However, major breakthroughs are still awaited.
• Clinical Trials and AI in Aging Research: Despite AI's potential to streamline early discovery, the complex and lengthy clinical trial process remains a bottleneck, often taking over a decade to deliver results.
• Public Understanding as a Catalyst: Public skepticism about longevity technologies limits political and financial support. A landmark success in human or pet longevity could act as a turning point.
• Pioneers and Innovations in the Field: Organizations like Calico and Altos Labs, with billions in funding, are making strides in aging research. Collaborative efforts like the Rejuvenation Roadmap consolidate data for broader engagement.
• AgingBiotech.Info: Pfleger’s platform consolidates resources for longevity research, including companies, databases, and advocacy tools. Plans for expansion include community contributions to keep pace with the field's growth.